Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

The Role of a Novel RNA in Beta2-Adrenergic Receptor Down-regulation

EF 2010-11

Résumé
Asthma is one of the most prevalent chronic conditions affecting Canadians. According to the Public Health Agency of Canada, over 2.2 million Canadians have been diagnosed with asthma by a physician. Asthma places a heavy burden on the nation's health care expenditures and seriously affects the quality of life not only for individuals with asthma but also for their families. A hallmark symptom of asthma is constriction of the airway, which is triggered by stimuli including allergens, viral infection, exercise, and cold air. The most common medications for asthma dilate and relax the airway during an asthma attack. One important class of bronchodilators works by binding to and activating a molecule called the beta2-adrenergic receptor. Although this class of bronchodilator medications is highly effective, their chronic use often leads to drug tolerance, decreased drug efficacy, and increased hospitalization and emergency room visits. Our project aim is to use a novel genomic research method to study a newly discovered regulator of the drug tolerance mechanism. In the future, this new regulator could serve as a novel pharmaceutical target for combination therapies, and thereby improve the efficacy of bronchodilator- based therapies for asthma.
Programme
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
229506
Name
Hu Ruoxi
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The Role of a Novel RNA in Beta2-Adrenergic Receptor Down-regulation
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
Airway Smooth Muscle Cell; Asthma; Beta2 Adrenergic Receptor; Beta2 Agonist Therapy; Biomechanic Analysis; Bronchodilator; Genetic Screen; Microrna (Mirna); Receptor Down-Regulation; Rnai (Rna Interference)
Abstract
Asthma is one of the most prevalent chronic conditions affecting Canadians. According to the Public Health Agency of Canada, over 2.2 million Canadians have been diagnosed with asthma by a physician. Asthma places a heavy burden on the nation's health care expenditures and seriously affects the quality of life not only for individuals with asthma but also for their families. A hallmark symptom of asthma is constriction of the airway, which is triggered by stimuli including allergens, viral infection, exercise, and cold air. The most common medications for asthma dilate and relax the airway during an asthma attack. One important class of bronchodilators works by binding to and activating a molecule called the beta2-adrenergic receptor. Although this class of bronchodilator medications is highly effective, their chronic use often leads to drug tolerance, decreased drug efficacy, and increased hospitalization and emergency room visits. Our project aim is to use a novel genomic research method to study a newly discovered regulator of the drug tolerance mechanism. In the future, this new regulator could serve as a novel pharmaceutical target for combination therapies, and thereby improve the efficacy of bronchodilator- based therapies for asthma.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hu, Ruoxi
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~